New AIDS Vaccine Effective in Monkeys

Researchers have developed an experimental AIDS vaccine that helps monkeys with a form of the AIDS virus successfully control the disease for more than a year.

Louis Picker and his colleagues said Cytomegalovirus (CMV) works by priming the immune system to quickly attack the HIV virus when it first enters the body, a point at which the virus is most vulnerable.

About AIDS
AIDS or HIV is an epidemic disease, a potentially deadly infection that can be prevented with precautions. AIDS/HIV symptoms manifest long after the actual infection occurs.

CMV enables the immune system to be constantly on the alert for HIV.

Picker said he thinks it will be possible to have a vaccine ready to test in people within three years, reports the Daily Mail.

Researchers used different versions of the vaccine against a monkey form of the Aids virus, SIV (Simian Immunodeficiency Virus) with outstanding results.

Quiz on HIV Symptoms
Do you know that there are symptoms for each stage of HIV/AIDS? Learn more from our HIV Symptom Quiz but here’s a disclaimer – never go by symptoms alone. Symptoms only indicate the progression of the disease, while only a medical test can confirm it.

More than half the rhesus macaques treated responded to the point where even the most sensitive tests detected no signs of SIV.

To date, most of the animals have maintained control over the virus for more than a year, gradually showing no indication that they had ever been infected.

HIV/AIDS Risk Calculator
The HIV risk quiz helps you determine risk factors for HIV.

Unvaccinated monkeys infected with SIV went on to develop the monkey equivalent of Aids, caused by the collapse of their immune systems.

The findings suggest the vaccine could be effective enough to rid the body of immunodeficiency virus completely.

New Finding in Monkeys may Pave Way for Effective AIDS Vaccine
Some monkeys are born with a certain gene that can help boost vaccine protection against simian immunodeficiency virus (SIV).

Conventional antiretroviral therapies are able to control HIV infection, but cannot clear the virus from its hiding places within the immune system's white blood cells.

"The next step in vaccine development is to test the vaccine candidate in clinical trials in humans. For a human vaccine, the CMV vector would be weakened sufficiently so that it does not cause illness, but will still protect against HIV," said Picker.

CMV belongs to the herpes family of viruses, and like other members of the group never leaves the body once an infection has occurred.

'What's exciting about these findings is that for the first time a vaccine candidate has been able to fully control the virus in some animals,' said Wayne Koff, chief scientific officer at the International AIDS Vaccine Initiative (IAVI), which helped fund the research.

Koff said the findings also suggested the possibility that the immune system may eventually eliminate the virus altogether.

The findings appear in the journal Nature.

Source-ANI